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Recessive dystrophic epidermolysis bul-losa (RDEB) is a rare, devastating, heredi-tary mechanobullous disease of the skin 
in which patients have marked skin fragility, 
widespread bullae, and erosions that character-
istically heal with exuberant scarring and milia 
formation (Fine et al., 2014). Our laboratory and 
several others have long aspired to develop an 
effective treatment—a goal now seemingly far 
closer than we had dared hope only a few years 
ago. Here we summarize relevant laboratory-
based advances in understanding RDEB patho-
genesis as well as recent steps toward translating 
this knowledge into targeted therapies. 
RDEB is attributable to mutations in the 
COL7A1 gene that encodes type VII collagen 
(C7). C7 forms large structures called anchoring 
fibrils (AFs) that localize to the dermal–epider-
mal junction (DEJ) and are required for epider-
mal–dermal adherence (Fine et al., 2014). In 
human skin, both keratinocytes and fibroblasts 
synthesize C7 α1 chains that form homotrimeric 
C7 molecules. The cells then secrete C7 mol-
ecules into the high extracellular space of the 
papillary dermis. It is not clear how C7 in the 
papillary dermis actually gets to the DEJ to form 
AFs, but we demonstrated that C7 has specific 
binding domains for type IV collagen and lam-
inin 332 in the DEJ (Chen et al., 1997, 1999). 
Therefore, C7 likely binds to components of the 
DEJ, condenses into antiparallel dimers, and 
then forms AFs. Using normal mouse wound 
healing models and mouse RDEB models, we 
and others have learned that all one needs to do 
is get C7 into the high papillary dermis: it will 
then self-assemble and form correctly localized 
AFs (Chen et al., 2002; Ortiz-Urda et al., 2003; 
Remington et al., 2009; Wang et al., 2013; 
Woodley et al., 2003, 2004, 2007, 2013a).
The ultimate treatment for RDEB may be 
gene therapy, provided the RDEB patient’s skin 
cells have a normal COL7A1 gene and express 
normal, functional C7. The COL7A1 gene is 
quite large, more than 9 kb, which exceeds the 
gene-packaging capability of most viral vectors. 
Nevertheless, we used a fourth-generation len-
tiviral vector engineered to express full-length 
C7 and demonstrated that RDEB keratinocytes 
and fibroblasts, when infected with this vec-
tor, were then able to synthesize and secrete 
full-length C7 (Chen et al., 2002; Woodley et 
al., 2004). Therefore, one promising method of 
treating RDEB would be to take a biopsy from 
the patient, place the patient’s keratinocytes and/
or fibroblasts into tissue culture in the labora-
tory, gene-correct the cultured RDEB cells such 
that they now express full-length C7, and then 
transplant the gene-corrected cells back onto the 
RDEB patient as a cultured autograft. Scientists 
in the Department of Dermatology at Stanford 
have taken this approach using gene-correct-
ed cultured keratinocyte autografts and have 
achieved proof of principle for this approach 
in one RDEB patient. The Stanford team is 
now evaluating the safety and efficacy of this 
approach with other RDEB patients in a phase I 
clinical trial.
Using RDEB murine models and murine 
wound models, we (Woodley et al., 2003) and 
Ortiz-Urda and colleagues (Ortiz-Urda et al., 
2003) demonstrated that cultured dermal fibro-
blasts (either from normal human subjects or 
from RDEB patients, engineered to express C7) 
can be injected into murine skin or  transplanted 
RDEB skin equivalents and that the injected 
cells then secrete C7 into the papillary dermis. 
There, C7 incorporates into the DEJ, forms new 
AFs, and reverses the RDEB phenotype of poor 
epidermal–dermal adherence. Interestingly, we 
also showed that the cells could be administered 
intravenously (IV) and home to open wounds 
in the skin, promoting healing (Woodley et al., 
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2007). This suggests that such cells, injected IV into an RDEB 
patient, might localize within healing wounds and continu-
ally secrete C7 that can then incorporate into the DEJ and 
form new AFs that promote healing. 
Along the lines of cellular therapy for RDEB, two stud-
ies attempted to treat RDEB patients with intradermal injec-
tions of normal cultured dermal fibroblasts obtained from 
closely related relatives (Wong et al., 2008; Venugopal et 
al., 2013). These injected cells did not persist in the skin 
very long, but the treated RDEB patients had increased C7 
expression at their DEJ and improved skin fragility and blis-
tering. The increased C7, however, was not produced by the 
injected normal fibroblasts. Rather, the allogeneic fibroblasts 
or perhaps even the process of creating an injection wound 
itself (Venugopal et al., 2013) stimulated the RDEB patients’ 
endogenous skin cells to synthesize increased amounts of 
mutated C7. Although the C7 was mutated, it was partially 
functional. Therefore, increased endogenous mutated C7 
improved the epidermal–dermal adherence of these RDEB 
patients, leading to clinical improvement.
Cell therapy for RDEB has also been demonstrated using 
another approach: delivery of allogeneic bone marrow/stem 
cells from normal relatives of RDEB patients who were close-
ly HLA matched using a protocol similar to those used for 
the treatment of cancer and leukemia patients. This therapy 
requires immunosuppression and ablation of the patient’s 
normal bone marrow prior to the administration of the 
donor bone marrow/stem cells and has substantial inher-
ent risks. This therapy has been shown to have remarkably 
positive effects in some RDEB patients by increasing C7 at 
the patient’s DEJ, with subsequent improvement in their skin 
disease and quality of life (Wagner et al., 2010), although 
there were also some deaths and untoward side effects. 
Nevertheless, the success rate appears to be improving with 
this therapy as investigators optimize their protocols, reduce 
the intensity of immunosuppression, optimize the selection 
of candidates, and identify the best population of stem cells 
and more closely HLA-matched donors. 
Most collagens, if injected intravenously, activate platelets 
and the plasma clotting system and induce vascular apoplexy 
and death. C7 is different. C7 is soluble in neutral buffers and 
blood. Therefore, in addition to cellular therapy for RDEB, 
it might be possible to simply provide full-length functional 
C7 itself to patients, so-called “protein replacement thera-
py.” Our laboratory developed a method by which we could 
obtain milligram quantities of purified human recombinant 
C7 (rhC7) (Chen et al., 2002; Woodley et al., 2004). Using 
RDEB mouse models, we have shown that one can adminis-
ter rhC7 intradermally (Woodley et al., 2004; Remington et 
al., 2009), topically to wounds (Wang et al., 2013), or even 
IV (Woodley et al., 2013a) to these animals, and it will incor-
porate into the DEJ and form new human AFs, improve epi-
dermal–dermal adherence, and increase the survival of the 
animals. Importantly, the IV rhC7 only went to wounded 
skin and not to any internal organs (Woodley et al., 2013a). 
Because RDEB skin probably has widespread subclinical, 
microscopic wounds, conceptually, IV rhC7 could home to 
all of these skin sites and prevent frank skin blisters. We have 
completed toxicity studies in rats and minipigs with intrader-
mal rhC7 and found no untoward side effects (unpublished 
data). IV administration is appealing because patients with 
RDEB characteristically have widespread skin lesions as 
well as lesions in areas that are less accessible, such as the 
upper third of the esophagus. Safe IV administration of rhC7 
has been shown in several “preclinical” animal models (nor-
mal mice, RDEB mice, hypomorphic RDEB mice, and RDEB 
Golden Retriever dogs). Shire Pharmaceuticals (Dublin, 
Ireland) is currently exploring the possibility of developing IV 
rhC7 for use in RDEB patients. If IV rhC7 behaves in RDEB 
patients as it does in these preclinical animal models, it 
would home to the open or subclinical microscopic wounds, 
incorporate into the DEJ, generate new AFs, and improve, if 
not normalize, the epidermal–dermal adherence at that site. 
How often these patients would need to be treated with IV 
rhC7 to maintain improved epidermal–dermal adherence 
and prevent new blister formation remains unknown. Type I 
collagen injected into human skin for improvement in pho-
toaging, however, persists for about 6 months. In RDEB mice 
and RDEB dogs, injected rhC7 persists for months, but the 
half-life of rhC7 in human skin may differ. 
RDEB patients heal their skin wounds with severe scar-
ring that leads to esophageal strictures and fusion of the digits 
on their hands and feet (so-called “mitten” deformities). The 
conventional wisdom is that this occurs because the blister 
cleavage plane in RDEB is below the lamina densa zone of 
the DEJ. We recently found, however, that RDEB skin and 
cultured fibroblasts exhibit upregulation of profibrotic iso-
forms of transforming growth factor-β and its downstream 
signaling pathways, suggesting that the reason RDEB patients 
have such horrible scarring is because the absence of C7 pro-
duces a proscarring microenvironment. Further evidence that 
C7 may play a role in wound healing includes experiments 
in which exogenous rhC7 was administered to wounds topi-
cally or IV and, surprisingly, wound closure was dramati-
cally accelerated by promoting reepithelialization (Wang et 
al., 2013). Even more surprising, exogenously administered 
rhC7 to standardized murine skin wounds resulted in healed 
wounds with less scarring and an associated downregulation 
of fibrosis markers such as profibrotic forms of transforming 
growth factor-β, type I collagen, connective tissue growth 
factor, and α-smooth muscle actin–positive myofibroblasts 
(Wang et al., 2013).
Gentamicin, an aminoglycoside antibiotic, and its deriv-
atives are old drugs traditionally used to resolve serious 
Gram-negative bacterial infections and are known to be oto-
toxic and nephrotoxic in some patients. Interestingly, this 
class of antibiotics has been shown in some cases to have 
the ability to “read-through” premature stop codons gener-
ated by nonsense mutations in certain types of gene defects. 
Approximately 10–25% of RDEB patients have nonsense 
mutations resulting in a truncated C7 or no C7 at all. We 
recently identified, genotyped, and characterized clinically, 
histologically, immunologically, and by electron microsco-
py 22 bona fide RDEB patients (Woodley et al., 2013b), of 
whom two had nonsense COL7A1 mutations. We cultured 
their keratinocytes and fibroblasts with varying doses of ami-
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noglycoside antibiotics. Without aminoglycosides, these 
cells synthesized no C7. By contrast, in the presence of non-
cytotoxic doses of aminoglycosides, both the RDEB cultured 
keratinocytes and the fibroblasts synthesized and secreted 
full-length C7 at a level between 10 and 35% that of normal 
cells (Cogan et al., 2014). The C7 generated was structurally 
identical to normal C7 and incorporated correctly into the 
DEJ of a human skin equivalent in vitro. RDEB cells express-
ing C7 also exhibited a reversal of the abnormal cellular 
motility that is characteristic of RDEB cells. Finally, we gener-
ated 22 published RDEB nonsense mutations by site-directed 
mutagenesis and transfected these constructs into human 
293 epithelial cells. Without aminoglycosides, these cells 
produced no C7. By contrast, treatment of the cells with ami-
noglycosides induced C7 expression between 10 and 80% of 
the level of C7 expressed in cells transfected with an expres-
sion vector for normal C7. These data suggest that aminogly-
cosides administered judiciously and cautiously may provide 
benefit for selected RDEB patients with nonsense mutations 
that create premature stop codons. 
In summary, recent federally funded laboratory research 
has generated reagents and concepts that are currently being 
translated into therapies for the devastating disease recessive 
dystrophic epidermolysis bullosa. 
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